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http://dx.dImproved Early Outcomes Using a T Cell Replete Graft
Compared with T Cell Depleted Haploidentical
Hematopoietic Stem Cell Transplantation
Stefan O. Ciurea,1 Victor Mulanovich,2 Rima M. Saliba,1 Ulas D. Bayraktar,1
Ying Jiang,2 Roland Bassett,3 Sa A. Wang,4 Marina Konopleva,5 Marcelo Fernandez-Vina,6
Nivia Montes,1 Doyle Bosque,1 Julianne Chen,1 Gabriela Rondon,1 Gheath Alatrash,1
Amin Alousi,1 Qaiser Bashir,1 Martin Korbling,1 Muzaffar Qazilbash,1 Simrit Parmar,1
Elizabeth Shpall,1 Yago Nieto,1 Chitra Hosing,1 Partow Kebriaei,1 Issa Khouri,1
Uday Popat,1 Marcos de Lima,1 Richard E. Champlin1Haploidentical stem cell transplantation (SCT) has been generally performed using a T cell depleted (TCD)
graft; however, a high rate of nonrelapse mortality (NRM) has been reported, particularly in adult patients.
We hypothesized that using a T cell replete (TCR) graft followed by effective posttransplantation immuno-
suppressive therapy would reduce NRM and improve outcomes. We analyzed 65 consecutive adult patients
with hematologic malignancies who received TCR (N5 32) or TCD (N5 33) haploidentical transplants. All
patients received a preparative regimen consisting of melphalan, fludarabine, and thiotepa. The TCR group
received posttransplantation treatment with cyclophosphamide (Cy), tacrolimus (Tac), and mycophenolate
mofetil (MMF). Patients with TCD received antithymocyte globulin followed by infusion of CD341 selected
cells with no posttransplantation immunosuppression. The majority of patients in each group had active dis-
ease at the time of transplantation. Outcomes are reported for the TCR and TCD recipients, respectively.
Engraftment was achieved in 94% versus 81% (P 5 NS). NRM at 1 year was 16% versus 42% (P 5 .02). Ac-
tuarial overall survival (OS) and progression-free survival (PFS) rates at 1 year posttransplantation were 64%
versus 30% (P5.02) and 50% versus 21% (P5.02). The cumulative incidence of grade II-IV acute graft-versus-
host disease (aGVHD) was 20% versus 11% (P5.20), and chronic GVHD (cGVHD) 7% versus 18% (P5.03).
Improved reconstitution of T cell subsets and a lower rate of infection were observed in the TCR group.
These results indicate that a TCR graft followed by effective control of GVHD posttransplantationmay lower
NRM and improve survival after haploidentical SCT.
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Haploidentical hematopoietic transplant is an
alternative treatment option for patients without an
HLA matched related or unrelated donor [1]. Haploi-
dentical related donors provide a readily available
source of stem cells for transplantation [2]. Histori-
cally, haploidentical transplants have been associated
with intense bidirectional alloreactivity, with higher
rates of graft failure and graft-versus-host-disease
(GVHD) [3]. T cell depletion (TCD) has been suc-
cessfully used to reduce the incidence of GVHD
[4,5]. However, this approach has been associated
with a relatively high risk of nonrelapse mortality
(NRM), primarily due to infectious complications1835
1836 Biol Blood Marrow Transplant 18:1835-1844, 2012S. O. Ciurea et al.and slow immunologic reconstitution posttransplanta-
tion, particularly in adults and those with active malig-
nancy at the time of transplantation [6-9].
High-dose posttransplantation cyclophosphamide
(Cy) has been shown to attenuate GVHD in mouse
models, and early clinical studies with nonmyeloabla-
tive conditioning followed by Cy, tacrolimus (Tac),
and mycophenolate mofetil (MMF) have reported
a low rate of acute GVHD (aGVHD) and chronic
GVHD (cGVHD), and treatment-related mortality
in less than 20% of patients [10-12].
We evaluated outcomes of adult patients treated
with T cell replete (TCR) haploidentical hematopoi-
etic transplants andcompared themwitha retrospective
cohort of patients previously treated at our institution
with TCD haploidentical transplants, using the same
preparative regimen, as previously described [13].METHODS
Patients, Conditioning Regimen, Sources of
Stem Cells, and Recovery of T Cell Subsets
Sixty-five consecutive patients, age $18 years,
received a haploidentical transplant ($2 HLA-
mismatched antigens at HLA-A, HLA-B, HLA-C,
HLA-DRB1, and HLA-DQB1) at The University of
Texas M.D. Anderson Cancer Center after October
2001 on successive clinical trials: 33 patients received
a TCD transplant between October 2001 and February
2009, whereas 32 patients received an unmanipulated
TCR graft between February 2009 and March 2011.
The preparative regimen consisted of melphalan
140 mg/m2 on day 28, fludarabine 40 mg/m2/day on
days 26, 25, 24, and 23, and thiotepa 10 mg/kg on
day 27. For the TCD group, GVHD prophylaxis in-
cluded rabbit antithymocyte globulin at 1.5 mg/kg/
day on days26,25,24, and23, followed by infusion
of CD341 selected cells using a CliniMacs system
(Miltenyi Biotec, Auburn, CA) [13]. The TCR group
received an unmanipulated graft followed by Cy
50 mg/kg/day on days 13 and 14, with Tac and
MMF starting on day15, and continuing at least until
4months posttransplantation for Tac, and at least until
day 135 posttransplantation for MMF. In the last
11 patients, MMF was continued until day 100 due
to the development of aGVHD in several of the initial
patients. Six patients treated with a TCR haploidenti-
cal graft had reduced doses of melphalan (100 mg/m2)
and thiotepa (5 mg/kg), due to older age (.55 years)
and/or comorbidities.
TCR patients were treated on a clinical trial regis-
tered at ClinicalTrials.gov (http://clinicaltrials.gov/
ct2/show/NCT01010217) (N 5 19), or off study be-
cause of ineligibility or insurance denial of treatment
on study by the patient’s insurance carrier (N 5 13).
All patients provided written informed consent fortheir treatment, and the Institutional Review Board
of the University of Texas M.D. Anderson Cancer
Center approved this retrospective study.
All TCD recipients received peripheral blood pro-
genitor cells, whereas all TCR patients (except one)
received bone marrow (BM) as their stem cell source.
Patients who developed aGVHD $grade 2 were rou-
tinely treated with corticosteroids (methylpredniso-
lone 1-2 mg/kg in divided doses).
Reconstitution of T cell subsets, CD41, CD81,
CD41CD45RA1 (naive T cells), CD41CD45RO1
(memory T cells), CD32CD561 (natural killer [NK]
cells), CD191 (B cells), was assessed by flow cytome-
try of peripheral blood samples approximately on days
30, 90, and 180 posttransplantation (N5 18 TCR and
N 5 7 TCD, respectively).
All patients received similar standard antimicrobial
prophylaxis with voriconazole, valacyclovir, and
trimethoprim-sulfamethoxazole or pentamidine.
Patients received no prophylaxis for cytomegalovirus
(CMV) infection and were treated with ganciclovir
or foscarnet for CMV antigenemia or disease.
HLATyping, HLA Ab Testing, and Donor
Selection
Patients and donors were typed for alleles at
HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-
DQB1 by PCR amplification and oligonucleotide hy-
bridization using commercial kits from Invitrogen
(Carlsbad, CA), ELPHA, and/or One Lambda (Can-
oga Park, CA) that achieved intermediate resolution.
The patients were also typed for these loci by high-
resolution methods using PCR amplification and
nucleotide sequencing (Abbott, Abbott Park, IL).
Additional high-resolution tests for selected loci
were done in the donors in whom an allele level mis-
match could not be ruled out. HLA haplotypes were
assigned by the analysis of the segregation of HLA
alleles as genetically transmitted units. HLA matching
was evaluated from the intermediate and high-
resolution results of the patients and the donors.
Donors were selected with consideration of a nega-
tive serum sample for donor-specific anti-HLA Abs
before transplantation [14], being ABO matched
rather than mismatched, male rather than female, and,
if feasible, by the presence of killer immunoglobulin-
like receptor (KIR)-ligand-mismatch in the graft-
versus-host direction [15].
Definitions
Engraftment was defined as achieving an absolute
neutrophil count (ANC)$5 109/L for 3 consecutive
days before day 28, with donor-derived cells detected
by microsatellite analysis [16]. Platelet recovery was
defined as achieving a platelet count $20  109/L un-
supported by platelet transfusions for 7 days. Primary
Biol Blood Marrow Transplant 18:1835-1844, 2012 1837TCR vs. TCD Haploidentical SCTgraft failure was defined as failure to achieve an ANC
$5  109/L before day 28. Acute and cGVHD were
defined and graded according to previously described
criteria [17,18]. Toxicity was scored using the
National Cancer Institute criteria (available at http://
ctep.info.nih.gov/reporting/ctc.html).
Infectious episodes were clinically documented if
fever or other signs and symptoms of infection were
present, along with laboratory and/or radiographic
features consistent with pulmonary, sinus, brain, gas-
trointestinal, skin and soft tissue, or other organ infec-
tion, but no pathogen was identified. An infection was
considered microbiologically documented if, in addi-
tion to the above findings, a disease-causing organism
was identified from a body fluid or tissue sample by
microbiologic or molecular testing or pathology. Pol-
ymicrobial infection was defined as more than 1
microorganism detected in the same body fluid or tis-
sue sample. Fever with or without neutropenia, or
without clinical or microbiological documentation,
was excluded from reporting. Mild infections 1/M
those not causing significant symptoms, not requiring
therapy or hospitalization 1/Mwere excluded. All tem-
porally related positive blood cultures for the same or-
ganismwere considered a single episode of bacteremia.
For coagulase-negative Staphylococcus, more than 1
positive culture was needed to diagnose bacteremia
in a symptomatic patient [19].
CMV infection and disease were diagnosed using
standard guidelines [20]. The presence of an invasive
fungal infection was determined based on the revised
definitions of the European Organization for Research
and Treatment of Cancer/Mycoses Study Group con-
sensus group [21].Death associatedwith a documented
infection was defined as death of a patient with findings
consistent with infection, or as detection of the patho-
gen at autopsy [22]. Patients were censored for graft
failure, death, or relapse.Statistical Analysis
The primary objectives were to compare the NRM,
engraftment, incidence of GVHD, immune
reconstitution, and infectious complications between
TCR and TCD haploidentical transplants. Other end-
points included overall survival (OS), progression-free
survival (PFS), and disease progression. Actuarial OS
and PFS were estimated based on the Kaplan-Meier
method. The cumulative incidence of progression,
NRM, and GVHDwas estimated, accounting for com-
peting risks for each outcome. Death in remission was
considered a competing risk for progression, disease
progression a competing risk for NRM, and disease
progression or death before GVHD as competing risks
for GVHD. Outcomes were compared between the
TCR and TCD groups on univariate analysis using
the Cox proportional hazards regression analysis.Patient and transplantation characteristics were com-
pared between the 2 groups using chi-square and the
Fisher exact tests for categorical variables and the Wil-
coxon rank sum test for continuous variables. Statistical
significance was defined at the 5% level. Analysis was
performed using STATA 9.0 (StataCorp 2005, College
Station, TX). For assessment of infections, descriptive
statistics, including frequency (percentages) for cate-
gorical variables and median (range) for quantitative
variables, were used to summarize infections and mor-
tality data. The effects of transplantation source on in-
fections were investigated by survival analysis. Patients
were followed up for 180 days from stem cell transplan-
tation (SCT) to observe infections. Because some pa-
tients had multiple infection episodes during the
follow-up time period, survival analysis of recurrent
events data was performed. All statistical analyses were
performed using SAS 9.1 (SAS Institute Inc., Cary,
NC) [23-25].
RESULTS
Patient characteristics are summarized in Table 1.
Patients in the TCR group tended to be older (median
age 45 versus 36 years; P 5 .06), and 28% versus 6%
were older than 50 years (P5 .02). All patients had he-
matologic malignancies; the most common diagnoses
were acute myeloid leukemia/myelodysplastic syn-
drome (Table 1). Most of the patients were not in re-
mission from their malignancies in both groups.
Twelve of 20 patients (60%) with acute leukemia in
the TCR group had poor-risk cytogenetics versus 14
of 30 patients (47%) in the TCD group (P 5 .30).
The donors were 5/10 allele match for the majority
of patients in both groups. Fifty-six percent and 42%
of patients received transplantation from a sibling do-
nor in the TCR and TCD groups, respectively. There
were no significant differences in number of HLA al-
lele mismatches or sex mismatch between the donor
and the recipient in the 2 groups (Table 1). Stem cell
source was primarily BM in the TCR group and pe-
ripheral blood CD341 selected progenitor cells in
the TCD group (Table 1). As a result, the number of
CD341 cells (median 2.5 versus 10.1  106/kg) and
number of CD31 cells infused (17 versus 0.01 
106/kg) differed significantly (P\ .0001) between the
TCR and TCD groups.
Transplant Outcomes
As of September 2011, the median follow-up
among surviving patients was 11 months (range, 6-28
months) for the TCR group and 48 months (range,
11-76 months) for the TCD group. One patient in
each group died within the first month posttransplan-
tation. The primary cause of death was attributed to
sepsis/pneumonia for the patient in the TCD group
(day 127) and respiratory syncytial virus infection
Table 1. Characteristics of 65 Patients Treated with TCR and
TCD Haploidentical SCTat M.D. Anderson Cancer Center
TCR, N 5 32 TCD, N 5 33 P Value
Median follow-up
survivors (months)
11 (6-28) 48 (11-76)
Disease status*
Active disease at
transplantation
19 (59%) 21 (64%) .70
Age at transplantation
Median (range) 45 (20-63) 36 (18-56) .06
>50 years 9 (28%) 2 (6%) .02
Sex, female 13 (41%) 17 (52%) .40
Diagnosis
AML/MDS 16 (50%) 26 (79%)
ALL 4 (13%) 4 (12%)
CML 5 (16%) 2 (6%)
NHL/CLL 3 (9%) 1 (3%)
HD 2 (6%) 0 (0%)
Other 2 (6%) 0 (0%)
Cytogenetics†
Poor-risk 12/20 (60%) 14/30 (47%) .30
Intermediate/good-risk 8/20 (40%) 16/30 (53%)
Conditioning
Ablative 26 (81%) 33 (100%)
Reduced-intensity 6 (19%) 0 (0%)
Donors
Siblings 18 (56%) 14 (42%) .20
Parent/child 13 (41%) 19 (58%)
Other 1 (3%) 0 (0%)
Number of mismatches
5 20 (63%) 17 (52%) .30
4 5 (16%) 5 (15%)
3 4 (13%) 6 (18%)
2 3 (9%) 3 (9%)
4 of 8† 0 (0%) 2 (6%)
Sex mismatch 16 (50%) 17 (52%) .90
Cell type
BM 31 (97%) 0
Peripheral blood 1 (3%) 33 (100%)
TCR indicates T cell replete; TCD, T cell depleted; SCT, stem cell trans-
plantation; AML, acute myeloid leukemia; MDS, myelodysplastic syn-
dromes; ALL, acute lymphoblastic leukemia; CML, chronic myeloid
leukemia; NHL, non-Hodgkin’s lymphoma; CLL, chronic lymphocytic
leukemia; HD, Hodgkin disease; BM, bone marrow.
*Patients with CML in chronic phase were considered in remission at
transplantation.
†For patients with ALL andMDS, cytogenetics were categorized as high-
risk if del5, del7, +8, del7q, abnormalities involving 3q, 9q, 11q, 20q, 21q,
17, or more than 3 abnormalities were present; good-risk cytogenetics
included t(8;21), inv(16), or t(16;16); intermediate-risk included diploid
cytogenetics or other chromosomal abnormalities.
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patient had upper respiratory symptoms before trans-
plantation, which progressed to pneumonia immedi-
ately posttransplantation.
Engraftment of neutrophils occurred in 94%
versus 81% for patients in the TCR and TCD groups,
respectively (P5 .10). Three and 2 patients had mixed
chimerism in the TCR and TCD groups, respectively;
the rest had complete donor chimerism for both mye-
loid and T cells. Follow-up chimerism and outcomes
for patients with mixed chimerism was as follows: (1)
for the TCD group, of the 2 patients with mixed
chimerism on day 30, 1 patient with acute myeloge-
nous leukemia (AML) developed graft failure in thepresence of donor-specific anti-HLA Abs, underwent
a retransplantation, and died of disease progression,
whereas the other patient lost T cell chimerism on
day 60 and died of disease relapse. (2) For the TCR
group, all 3 patients with mixed chimerism had
reduced-intensity conditioning and 2 of them had
chronic lymphocytic leukemia (CLL). One patient
with CLL lost the graft at day 60 and underwent a re-
transplantation with nonmyeloablative conditioning
including fludarabine/Cy/total body irradiation [12],
and is alive and in remission at last follow-up; 1 patient
with CLL had mixed chimerism on day 30, lost the
graft on day 60 in the presence of very high HHV-6
viremia, and later died of disease relapse; the third pa-
tient with AML had high mixed chimerism at day 60
(98% T and 82% M cells) and remains in molecular
complete remission at more than 1 year posttransplan-
tation.Most recent chimerism for this patient was 96%
T and 83% M cells.
Recovery of neutrophils occurred after a median of
18 days (range, 5-24 days) and 13 days (range, 9-26
days; P 5 4.8), and platelets after a median of 26 days
(range, 11-307 days) versus 12 days (range, 7-48 days;
P5 .03) in theTCRversus theTCDgroup, respectively
(Table 2).
The cumulative incidence of grade II-IV aGVHD
within 100 days was 20% versus 11% (P 5 .20) and
grade III-IV was 5% versus 9% (P 5 .59) for TCR
and TCD recipients, respectively. The rate of
cGVHDat 1 year was low in both groups, with a cumu-
lative incidence of 7% versus 18% (P 5 .03) in the
TCR and TCD group, respectively (Table 2,
Figure 1). No patient developed extensive cGVHD
in the TCR group.
OS and PFSwere superior in the TCR group when
compared at day 100 and at 1 year after transplantation
(Table 2, Figure 1). Actuarial OS and PFS rates at 1
year posttransplantation were 64% versus 30% (P 5
.02) and 50% versus 21% (P5 .02) for the TCR versus
TCD groups, respectively. OS (92% versus 33%; P 5
.02) and PFS (82% versus 25%; P5 .01) remained sig-
nificantly superior in the TCR group when analysis
was restricted to patients who were in remission at
transplantation.
Better survival was related to a significantly lower
rate of NRM in the TCR group; the rate of relapse or
progression of malignancy was not different between
the 2 groups (Table 2, Figure 1). The day 100 cumu-
lative incidence of NRM was 12% for the TCR group
versus 21% for the TCD group (P 5 .30). The differ-
ence became more pronounced at 1 year posttrans-
plantation, showing a significantly lower incidence
of NRM in the TCR group (16% versus 42%;
P 5 .02). For patients in remission, NRM was signif-
icantly lower in the TCR group both at day 100 (0%
versus 42%; P 5 .01) and 1 year posttransplantation
(0% versus 67%; P 5 .001).
Table 2. Outcomes for Patients Treated with a TCR versus a TCD Haploidentical Graft Using the Same Conditioning Regimen
TCR
N 5 32
TCD
N 5 33 HR 95% CI P Value
Primary engraftment 94% (29/31) 81% (26/32) .10
ANC 500/mL (days), median (range) 18 (5-24)
N 5 29
13 (9-26)
N 5 27
4.8
PLT 20,000/mL (days), median (range) 26 (11-307)
N 5 25
12 (5-24)
N 5 24
.03
ALC 1000/mL (days), median (range) 127 (44-423)
N 5 15*
65 (27-273)
N 5 13
.10
CI grade II-IV aGVHD† (day 100) 20% (10-41)
N 5 30
11% (4-32)
N 5 27
1.6 0.4-6.4 .20
cGVHD (at 1 year) 7% (2-28)
N 5 30
18% (8-41)
N 5 27
0.2 0.03-0.98 .03
Day 100 outcomes
Overall N 5 32 N 5 33
OS 84% (66-93) 76% (57-87) 0.6 0.2-1.9 .40
PFS 81% (63-91) 61% (42-75) 0.4 0.2-1.1 .08
Progression 6% (2-24) 18% (9-37) 0.3 0.1-1.5 .10
NRM 12% (5-31) 21% (11-41) 0.5 0.2-1.8 .30
Day 100 outcomes
No active disease at transplantation N 5 13 N 5 12
OS 100% 58% (27-80) N/A .01
PFS 100% 58% (27-80) N/A .01
Progression 0% 0% N/A N/A
NRM 0% 42% (21-81) N/A .01
Outcomes at 1 year
Overall
OS 64% (44-78) 30% (15-46) 0.4 0.2-0.85 .02
PFS 50% (31-67) 21% (9-36) 0.5 0.2-0.9 .02
Progression 34% (20-57) 36% (23-57) 0.6 0.3-1.5 .30
NRM 16% (7-35) 42% (28-63) 0.3 0.1-0.8 .02
Outcomes at 1 year
No active disease
OS 92% (57-99) 33% (10-59) 0.1 0.01-0.7 .02
PFS 82% (44-95) 25% (6-50) 0.1 0.03-0.7 .01
Progression 18% (5-64) 8% (1-54) 1.03 0.1-11 .90
NRM 0% 67% (45-99) N/A .001
TCR indicates T cell replete; TCD, T cell depleted; HR, hazard ratio; CI, confidence interval; ANC, absolute neutrophil count; PLT, platelet count; ALC,
absolute lymphocyte count; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; OS, overall survival; PFS, progression-
free survival; NRM, nonrelapse mortality; N/A, not applicable.
*Three patients could still recover ALC to 1000/mL at the time of evaluation.
†aGVHD within 100 days.
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Transplantation
Improved NRM in the TCR group was accompa-
nied by a better immune reconstitution of T cell sub-
sets in the first 6 months posttransplantation
(Figure 2). On day 30 posttransplantation, a 20-fold
greater number of CD41 and CD81 T cells were
observed among evaluable patients in the TCR group
(N 5 18) compared to the TCD group (N 5 7). The
median number of absolute CD41 cells in the TCR
group was 26 versus 1/mL (P 5 .00084; N 5 25), and
themedian number of absolute CD81 cells was 22 ver-
sus 1/mL (P5 .006; N5 25), respectively. The CD41
T cells remained significantly lower in the TCD group
until after day 180, when the median absolute CD41
count was 194/mL in the TCR compared with 69/mL
in the TCD group (P 5 .04). The absolute CD81
counts also seemed to be higher at day 180 in the
TCR group (median 167 versus 54/mL); however, it
did not reach statistical significance (P 5 .40)
(Figure 2).Improved immune reconstitution was also noted
for naive and memory T cells in the TCR group.
The median absolute numbers of CD41CD45RA1
(naive T cells) and CD41CD45RO1 (memory T
cells) were higher at day 30 and at day 90 posttrans-
plantation, 3.4 versus 0.7/mL and 7.3 versus 0.55/mL
for the naive T cells, and 24 versus 2.6/mL and 97 ver-
sus 16/mL for the memory T cells between the TCR
and the TCD groups, respectively (Figure 2). Interest-
ingly, there was a higher proportion of CD3-CD561
NKcells at all time points in the TCDgroup, although
these differences were not statistically significant. The
number of CD191 B cells was similar between the 2
groups during the first 6 months posttransplantation
(Figure 2). After day 180, there were no significant dif-
ferences in any lymphocyte subsets.
Infectious Complications in TCR and TCD
Haploidentical Transplants
The incidence of viral and fungal infections was
significantly lower when compared to the TCD
Figure 1. Outcomes of T cell replete (TCR) and T cell depleted (TCD) haploidentical transplant patients treated with fludarabine, melphalan, and
thiotepa conditioning. (A) Progression-free survival for all patients. (B) Progression-free survival for patients in remission at transplantation. (C)
Non-relapse mortality for all patients. (D) Non-relapse mortality for patients in remission at transplantation. (E) Cumulative incidence of chronic
graft-versus-host disease (cGVHD). (F) Cumulative incidence of grade II-IV acute graft-versus-host disease (aGVHD).
1840 Biol Blood Marrow Transplant 18:1835-1844, 2012S. O. Ciurea et al.group (Table 3). There was a trend for a lower prob-
ability of developing any infection in the first
6 months posttransplantation in the TCR group
(P 5 .06).Viruses were themost common cause of infection in
both groups. During the first 180 days posttransplanta-
tion, therewere 22 episodes per 1000 patient-days in the
TCD group and 11 episodes per 1000 patient-days in
Figure 2. Recovery of T cell subsets after transplant in T cell replete (TCR) and T cell depleted (TCD) haploidentical stem cell transplantations.
**P\.002 (with Bonferroni correction); *P . .002\ .05. (A) Recovery of absolute CD81 cell numbers (median). (B) Recovery of absolute CD41
cell numbers (median). (C) Recovery of absolute CD41CD45RA1 cell numbers (naive T cells) (median). (D) Recovery of absolute
CD41CD45RO1 cell numbers (memory T cells) (median). (E) Recovery of absolute CD561 cell numbers (natural killer [NK] cells) (median).
(F) Recovery of absolute CD191 cell numbers (B cells) (median).
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tation. Patients in the TCD group were 1.5 times (95%
confidence interval [CI]: 1.03-2.1) more likely to
develop a viral infection (P 5 .035) during this timeTable 3. Infectious Complications in the First 180 Days Postt
Haploidentical Transplant Groups
Type of Transplant TCD Haploidentical (N 5 33)
Type of Infection
No. of
Episodes
No. of Infected
Patients
No. of Episodes/
1000 pt-days
Viral 82 24 22.2
Bacterial 38 21 10.3
Fungal 12 11 3.2
Parasite 2 2 0.5
Total infection episodes* 146 30 39.4
TCD indicates T cell depleted; TCR, T cell replete; pt, patient.
*Includes viral, bacterial, fungal infections, and all others such as clinically docuperiod (Table 3). Among the viral infections, CMV
reactivation and human polyomavirus BK cystitis were
the most frequent. Fourteen of 33 patients (42.2%)
had CMV reactivation with a total of 30 episodes inransplantation by Causative Agent in the TCR and TCD
TCR Haploidentical (N 5 32) Survival Analysis
No. of
Episodes
No. of Infected
Patients
No. of Episodes/
1000 pt-days P Value
50 27 10.8 .035
32 19 6.9 .66
3 3 0.6 .008
0 0 0 .17
91 31 19.7 .06
mented and parasitic infections.
1842 Biol Blood Marrow Transplant 18:1835-1844, 2012S. O. Ciurea et al.the TCD group compared with 15 of 32 patients
(46.8%) with 24 episodes in TCR group. For human
polyomavirus BK cystitis, 15 of 33 cases (45.4%) were
found in the TCD group versus 11 of 32 (34.4%) in
the TCR group.
There was no significant difference in the inci-
dence of bacterial infections between the 2 groups.
Thirty-two bacterial infections occurred in the TCR
group compared with 38 episodes in the TCD group.
On average, 7 and 10 episodes occurred per 1000
patient-days for the TCR and TCD group, respec-
tively.
Invasive fungal infections were third in frequency,
with 12 episodes in 11 of 33 patients (33%) in the
TCD group, and only 3 episodes in 3 of 32 patients
(9%) in the TCR group. The TCR group had a signif-
icantly lower probability of having a fungal infection
(P 5 .008). Patients in the TCD group were 5.6 times
(95%CI: 1.6-20.2) more likely to have an invasive fun-
gal infection within 6 months posttransplantation than
those in the TCR group (Table 3).
Survival analysis revealed a significantly lower
probability of death from an infection in the TCR
group. The NRM attributed to infections was 24% in
the TCD group and 9% in the TCR group (P 5 .01).DISCUSSION
No direct comparison between T cell depleted and
TCR haploidentical transplants has been reported to
date. Some centers reported success with TCD haploi-
dentical transplants, particularly in children and young
adults and patients in remission [26,27]. Our center
and others have experienced a relatively high rate of
treatment-related mortality in adult patients using
a similar approach [13]. Our results seem similar to
other large series involving adult patients, most with
active disease at the time of transplantation [28].
We analyzed the early results of haploidentical
transplants in adult recipients treated on 2 successive
studies, and report improved outcomes with TCR
transplants, using posttransplantation Cy, Tac, and
MMF for GVHD prevention. The study evaluated
patients on sequential protocols; the majority of
patients had active malignancy at the time of trans-
plantation. Uniform policies for supportive care were
used for both cohorts of patients. We have found
a lower rate of treatment-related mortality and associ-
ated improved immune reconstitution of T cell subsets
in the TCR group. The rate of aGVHD was relatively
low in both groups. Although depletion of mature
T cells from the graft was an effective method of con-
trolling GVHD in the TCD group, the T cell recovery
posttransplantation was significantly delayed; this was
associated with higher incidence of infectious compli-
cations and NRM. We have also observed a 5-foldlower incidence of fungal infections and almost
2-fold lower incidence of viral infections in patients
receiving a TCR haploidentical transplant.
Previous studies have reported on prolonged
immune deficiency and higher risk of infectious com-
plications in TCD haploidentical transplant recipients
[29-33]. Pirsch et al. [29] initially showed that recipi-
ents of HLA-matched TCD transplants had signifi-
cantly higher incidence of fungal infections, whereas
the highest risk of such infections was noted in
mismatched TCD transplants. Overall, 83% of the
mismatchedTCD transplants and 55% of thematched
TCD transplants died of infection [29]. T cell deple-
tion was a strong independent predictor of invasive
fungal infection in multivariate analysis [29]. Among
patients who developed a deep fungal infection, the
highest risk was found among mismatched transplan-
tations with TCD, followed by matched transplanta-
tions with TCD and matched without TCD [29].
Slow reconstitution of CD41 cells was previously rec-
ognized in TCDmarrow transplants, with low-normal
levels being reached approximately 6 months post-
transplantation [30]. Daley et al. [31] have shown
that regeneration of the T cell compartment was
more severely impaired during the first 180 days
post-TCD transplant than in those who received un-
treated marrow, and these patients had a greater rate
of infections and disease recurrence. Recipients of
TCD marrow grafts had lower proportions of cyto-
toxic and proliferative T cells in the first 6 months
posttransplantation [31]. These studies are consistent
with our finding of a higher rate of infections and
treatment-related mortality early posttransplantation.
There are several limitations to our study, primar-
ily related to a relatively small number of patients an-
alyzed and the treatment of patients on sequential
studies. Because of that, no multivariate analysis could
be performed. The follow-up period for the TCR
group is shorter than for TCD recipients; however,
we ensured that all patients had at least 6 months’
follow-up in order to directly compare the outcomes
between the 2 groups during the early posttransplanta-
tion period. Patient characteristics in each group were
similar. When the analysis was restricted to patients
with AML only, the same pattern and differences
were found (data not shown).
In conclusion, this analysis demonstrates the feasi-
bility of myeloablative TCR haploidentical transplants
using fludarabine, melphalan, and thiotepa condition-
ing, and that this type of transplantation can be per-
formed with a low rate of aGVHD and cGVHD
using posttransplantation Cy, Tac, and MMF as post-
transplantation immunosuppressive therapy. Better
immune reconstitution could have contributed to im-
proved early NRM. This approach for haploidentical
transplant is an effective treatment option for patients
lacking an HLA-identical related or unrelated donor.
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